Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of March 2023. The report, dated March 13, 2023, incorporates by reference a press release (Exhibit 99.1) and is signed by Mondher Mahjoubi, Chairman of the Executive Board and CEO.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a procedural filing to incorporate a press release rather than a detailed financial statement.
Material Changes
The filing text does not disclose specific material changes versus prior periods. The content is limited to the incorporation of a press release dated March 13, 2023, without summarizing the operational or financial details contained within that release.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. These details are presumed to be located in the referenced Exhibit 99.1 (Press Release), which is not included in the provided input text.
Investor Verification Checklist
- Review the full text of the Press Release dated March 13, 2023 (Exhibit 99.1) for specific operational updates.
- Verify the content of the registration statement on Form F-3 (File No. 333-252074) into which this report is incorporated.
- Check subsequent filings for any superseding information regarding the March 2023 period.